2月25日，九源基因（02566.HK）发布公告称，公司自主研发的司美格鲁肽注射液减重适应症（吉可亲）上市许可申请已获得国家药品监督管理局（NMPA）正式受理，本次申报的适应症为肥胖或超重人群的体重管理。在国内司美格鲁肽减重适应症领域，公司属于少数已完成上市申报并进入审评阶段的企业之一。在具体技术路径上，国内相关产品的研发路线存在差异。目前，部分企业采用化学合成路线进行制备；九源基因则依托自身在...
Source Link2月25日，九源基因（02566.HK）发布公告称，公司自主研发的司美格鲁肽注射液减重适应症（吉可亲）上市许可申请已获得国家药品监督管理局（NMPA）正式受理，本次申报的适应症为肥胖或超重人群的体重管理。在国内司美格鲁肽减重适应症领域，公司属于少数已完成上市申报并进入审评阶段的企业之一。在具体技术路径上，国内相关产品的研发路线存在差异。目前，部分企业采用化学合成路线进行制备；九源基因则依托自身在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.